Expanding Diagnostic Portfolio Rheonix offers a versatile and automated molecular diagnostic platform that caters to various market sectors, including reference labs and point-of-care settings, presenting opportunities to supply integrated testing solutions for diverse healthcare providers.

Recent Partnerships & Collaborations Strategic alliances with Eurofins and the FDA on pathogen detection and food safety tests indicate a strong foothold in regulatory-approved testing, opening avenues to sell specialized diagnostic assays to public health agencies and food safety companies.

COVID-19 Testing Expertise With a proven track record of COVID-19 PCR testing launched in 2020, Rheonix has existing infrastructure and expertise that can be expanded or adapted to develop new infectious disease assays, appealing to health systems and outbreak monitoring programs.

Innovative Assay Development Ongoing development of multiplex tests that detect multiple pathogens simultaneously positions Rheonix to address the growing demand for comprehensive respiratory panels, creating sales opportunities with hospitals, clinics, and laboratories seeking rapid, multiplex diagnostics.

Market Position & Scalability With a moderate-sized workforce and revenue between $10 million and $25 million, Rheonix is positioned for targeted growth through strategic expansion into high-demand diagnostic markets, especially where automation and affordability are critical for widespread adoption.